COVID-19: TCTMD’s Daily Dispatch for September 22
UK raises COVID-19 alert level, CDC removes airborne transmission info, prevalent heart problems in MIS-C, and more.
UK raises COVID-19 alert level, CDC removes airborne transmission info, prevalent heart problems in MIS-C, and more.
Although ORBITA-AF shows it can be done, and other trials are underway, not everyone is convinced it’s worth the effort.
It’s possible that other classes of antithrombotics may be worth adding to improve reperfusion, but that’s conjecture right now.
”Zero-degree positioning” may be one of the most important first steps in managing large vessel occlusions, study shows.
The findings shouldn’t, however, discourage those who want children from pursuing ART, experts say.
In an EHRA debate, experts grappled with how to interpret promising preliminary data while longer-term trials are ongoing.
Initial safety and efficacy findings from this first-in-human series “look really impressive,” but experts await further studies.
In an EHRA debate, experts grappled with how to interpret promising preliminary data while longer-term trials are ongoing.
As demand for the drug continues to rise, alternatives like the oral formulation and other injectable GLP-1s come into play.
The first-in-human results represent “an encouraging first step with a novel ablation source,” one expert says.
Findings from a Finnish study don’t reveal a reason for the trend, but some speculate it could be due to better risk factor control.